Our top pick for
GAN Limited is a gambling business based in the US. GAN shares (GAN) are listed on the NASDAQ and all prices are listed in US Dollars. GAN employs 242 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$15.18|
|52-week range||$13.04 - $31.81|
|50-day moving average||$15.54|
|200-day moving average||$16.62|
|Wall St. target price||$23.60|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.51|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-12)||9.21%|
|1 month (2021-09-17)||-6.81%|
|3 months (2021-07-19)||0.53%|
|6 months (2021-04-19)||-13.90%|
|1 year (2020-10-19)||-4.47%|
|2 years (2019-10-15)||N/A|
|3 years (2018-10-15)||N/A|
|5 years (2016-10-15)||N/A|
Valuing GAN stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of GAN's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
GAN's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $2.1 million.
The EBITDA is a measure of a GAN's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$81.6 million|
|Gross profit TTM||$24.7 million|
|Return on assets TTM||-6.38%|
|Return on equity TTM||-11.64%|
|Market capitalisation||$639.1 million|
TTM: trailing 12 months
There are currently 2.5 million GAN shares held short by investors – that's known as GAN's "short interest". This figure is 14.9% up from 2.2 million last month.
There are a few different ways that this level of interest in shorting GAN shares can be evaluated.
GAN's "short interest ratio" (SIR) is the quantity of GAN shares currently shorted divided by the average quantity of GAN shares traded daily (recently around 620594.08866995). GAN's SIR currently stands at 4.06. In other words for every 100,000 GAN shares traded daily on the market, roughly 4060 shares are currently held short.
However GAN's short interest can also be evaluated against the total number of GAN shares, or, against the total number of tradable GAN shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case GAN's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 GAN shares in existence, roughly 60 shares are currently held short) or 0.0633% of the tradable shares (for every 100,000 tradable GAN shares, roughly 63 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against GAN.
Find out more about how you can short GAN stock.
We're not expecting GAN to pay a dividend over the next 12 months.
GAN's shares were split on a 1:4 basis on 3 May 2020. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your GAN shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for GAN shares which in turn could have impacted GAN's share price.
Over the last 12 months, GAN's shares have ranged in value from as little as $13.0391 up to $31.81. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while GAN's is 1.7745. This would suggest that GAN's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
GAN Limited operates as a business-to-business supplier of internet gambling software-as-a-service solutions to online casino gaming and online sports betting applications in the United States, Italy, the United Kingdom and Channel Islands, and internationally. The company operates through Real Money iGaming (RMiG) and Simulated Gaming (SIM) segments. It offers and licenses GameSTACK, a proprietary internet gambling enterprise software system as a turnkey technology solution for regulated real-money internet gambling, encompassing internet gaming, internet sports gaming, and virtual simulated gaming. The company also offers sports betting, online casino game, and peer-to-peer poker services through its Coolbet. com website, as well as a range of professional and managed services designed to deploy and provide ongoing operational support for its software systems. It serves regional operators and individual tribal casino operators. The company was founded in 2002 and is headquartered in Irvine, California.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.